IBRX
ImmunityBio, Inc.
NASDAQ · USHealthcareBiotechnology
$7.50-2.41%
Price as of Jul 20, 2026
IBRX valuation
ImmunityBio, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 17.39x
- P/S forward
- 15.55x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -9.02x
- Price / sales
- 55.68x
- Price / cash flow
- -26.67x
Enterprise value
- Enterprise value
- $8.6B
- EV / sales
- 60.96x
- EV / EBITDA
- -11.83x
- EV / EBIT
- -32.88x
- Market cap
- $7.8B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.